Everlab Raises $42M to Unite Diagnostics and Preventive Care in One Platform
Australian healthtech Everlab secures $42M to connect biomarkers, clinicians, and health data — catching disease risks before symptoms appear.
Summary
Everlab, a Melbourne-based healthtech startup, has raised $42 million to expand its preventive healthcare platform across Australia and New Zealand. Founded in 2023, the company integrates blood diagnostics, specialist referrals, prescriptions, and continuous health monitoring into a single system. Rather than waiting for disease to strike, Everlab aims to identify risk factors years in advance. In just three years, it has conducted over 40,000 consultations, processed 21 million biomarker results, and found that more than 25% of members had undetected health findings. The platform serves both individuals and corporate partners including Boston Consulting Group and BHP, signaling growing employer interest in proactive employee health.
Detailed Summary
Preventive healthcare is moving from concept to commercial reality, and Everlab's $42 million Series A raise is one of the clearest signals yet. The Melbourne-based startup has built what it calls a health operating system — a platform that aggregates diagnostics, clinician consultations, specialist referrals, and wearable data into one unified view. The funding round was oversubscribed and led by Airtree Ventures, with participation from Plural, Left Lane Capital, and b2venture.
The core problem Everlab is solving is fragmentation. Most people's health data is scattered across labs, specialists, apps, and email inboxes, with no single provider holding the full picture. This gap means early warning signs frequently go unnoticed until they become serious conditions. Everlab's platform is designed to close that gap by surfacing what the company calls health blind spots and coordinating next steps — from targeted screenings to personalized health plans.
The early numbers are striking. Since launching in 2023, Everlab has processed over 21 million biomarker results across more than 20,000 patients. More than 25% of members had clinically significant health findings that had not previously been identified — a figure that underscores just how much goes undetected in standard care.
Investor enthusiasm reflects a broader shift in how healthcare is being valued. Chronic diseases account for the majority of global healthcare spending, yet most systems remain structured around treating illness rather than preventing it. The longevity field has long argued for earlier intervention, and platforms like Everlab represent the commercial infrastructure to make that possible at scale.
Caveats remain. Everlab is a private company reporting its own outcomes data, so independent validation of its detection claims is not yet available. The platform currently operates in Australia and New Zealand, limiting immediate applicability elsewhere. Still, the model — centralizing biomarker tracking and proactive care coordination — points toward a scalable blueprint for preventive medicine globally.
Key Findings
- Over 25% of Everlab members had undetected health findings identified through comprehensive biomarker screening
- Platform has processed 21 million biomarker results across 20,000+ patients in under three years
- Raised $42M Series A less than a year after a $10M seed round, signaling strong investor conviction in preventive care
- Integrates diagnostics, specialist referrals, prescriptions, and wearable data into one coordinated health system
- Corporate partnerships with BCG, BHP, and Bain signal growing employer demand for proactive workforce health
Methodology
This is a news report summarizing a funding announcement and company overview from Longevity.Technology, a specialist industry publication. Evidence is based on company-reported metrics and investor statements rather than peer-reviewed research. No independent clinical validation of Everlab's detection outcomes is cited.
Study Limitations
All outcome data — including the 25% undetected findings statistic — is self-reported by Everlab and has not been independently verified or published in peer-reviewed literature. The platform currently operates only in Australia and New Zealand. Funding announcements can reflect market sentiment as much as clinical efficacy, so results should be interpreted cautiously until external validation is available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.